Abstract
Inflammatory processes play a key role in pathophysiology of many neurologic diseases/trauma, but the effect of immune cells and factors on neurotransplantation strategies remains unclear. We hypothesized that cellular and humoral components of innate immunity alter fate and migration of human neural stem cells (hNSC). In these experiments, conditioned media collected from polymorphonuclear leukocytes (PMN) selectively increased hNSC astrogliogenesis and promoted cell migration in vitro. PMN were shown to generate C1q and C3a; exposure of hNSC to PMN-synthesized concentrations of these complement proteins promoted astrogliogenesis and cell migration. Furthermore, in vitro, Abs directed against C1q and C3a reversed the fate and migration effects observed. In a proof-of-concept in vivo experiment, blockade of C1q and C3a transiently altered hNSC migration and reversed astroglial fate after spinal cord injury. Collectively, these data suggest that modulation of the innate/humoral inflammatory microenvironment may impact the potential of cell-based therapies for recovery and repair following CNS pathology.
Introduction
The efficacy of therapeutic neurotransplantation targeting CNS disease/trauma will be heavily dependent on interactions between donor cells and the cellular and molecular microenvironment. The importance of environmental cues for neural stem cell (NSC) properties became clear in early studies demonstrating region-specific fate profiles within the intact CNS (1, 2). Although the CNS has traditionally been considered immune privileged, neuroinflammation is now known to be a hallmark of neurodegeneration/trauma, including activation of innate and adaptive immunity and infiltration of a diverse array of inflammatory cells and molecules (3–7). We hypothesize that cross-talk between NSC and the immune system may be critical for both endogenous and donor cell responses in the injured, diseased, or aged CNS.
The immunomodulatory effects of donor stem cells on the host have been studied extensively, particularly in the case of mesenchymal stem cell populations, but also in the context of NSC populations (8–12). The converse, that is the effect of the host cellular immune response on donor stem cells, has received less attention. T cells, microglia, and their secreted components have been shown to alter the properties of NSC or neural progenitor/precursor cell (NPC) populations (9, 13–17). Both activated microglia and some of their secreted factors such as TNF-α and IL-6 have been previously described to inhibit neuron production both in vitro and in vivo (17, 18). Similarly, cytokines/chemokines and other pro- and anti-inflammatory molecules have been shown to regulate NSC/NPC survival, proliferation, fate, and migration (reviewed in Ref. 19). However, the effect of infiltrating innate immune cells and humoral components of the innate immune response, for example, neutrophils, macrophages (Mϕ), and cytokines/proteins of the complement cascade, on stem cells remains to be elucidated. In particular, expression of complement receptor CR2 by rodent NPC has recently been identified and shown as a regulator of adult neurogenesis (20), and C3a has been shown to modulate ischemia-induced astrocyte survival (21), suggesting that neural and glial cells can interact with components of the complement cascade.
In the current study, we investigated whether factors synthesized by immune cells that infiltrate the CNS acutely after injury could alter the fate and migration of human NSC (hNSC), thereby significantly influencing the therapeutic application of cell therapies in the clinical setting. We show that conditioned media (CM) derived from two distinct populations of immune cells, polymorphonuclear leukocytes (PMN) and Mϕ, alter migration and differentiation of hNSC in vitro. Furthermore, we identify complement components C1q and C3a as molecular mediators for these novel effects. Finally, in a proof-of-concept neurotransplantation experiment, we demonstrate that blockade of C1q and C3a in vivo can alter hNSC fate and migration in the acute phase of spinal cord injury (SCI), when both PMN infiltration and complement activation peak.
Materials and Methods
All procedures involving animals were conducted in accordance with the Institutional Animal Care and Use Committee guidelines at University of California, Irvine.
Generation of PMN or Mϕ-CM
CM was generated from PMN or Mϕ isolated from the peritoneal cavity of NOD-scid mice for all experiments, with the exception of the following: 1) Fig. 1H, in which immune-sufficient rats were used to replicate the effects of NOD-scid–derived CM on NSC, and 2) Supplemental Fig. 1B, 1C, in which knockout (KO) mice on the BUB/BnJ complement-sufficient background were specifically used to investigate the role of C1q/C3a in PMN-CM. NOD-scid mice were selected to enable comparison between in vitro (Figs. 1–8) and in vivo (Figs. 9, 10) data, in which donor human cells were xenografted into the mouse spinal cord. NOD-scid mice are T cell and B cell deficient, making this model optimal and widely used for xenotransplantation studies in which the survival of donor human cells is a critical variable (22). Importantly, although NOD-scid mice exhibit deficits in adaptive immunity, they demonstrate innate immune responses and histopathological characteristics comparable to other mouse strains following SCI (23).
Briefly, adult female mice received 12% sodium caseinate (i.p.) and were sacrificed 12–16 h later (to obtain PMN) or 3–5 d later (to obtain Mϕ), as described previously (24). The peritoneal exudate containing leukocytes was overlaid on Histopaque 1077 (Sigma-Aldrich) and centrifuged at 400 × g to separate PMN (12–16 h postsodium caseinate) or Mϕ (3–5 d postsodium caseinate) from other leukocytes, yielding 97% PMN and 80% F4/80+ Mϕ, respectively. Aliquots of isolated cells were mounted on slides and stained with a mouse anti-PMN Ab (1:500; Serotec), a mouse anti-F4/80 Ab (1:100; Serotec), and hematoxylin to confirm cell populations by nuclear morphology and quantify enrichment.
For CM generation, PMN or Mϕ were incubated in NSC differentiation medium (DM), composed of X-vivo media containing BDNF (10 ng/ml), GDNF (10 ng/ml), ciproflaxacin (10 mg/ml), N2 (1:100), heparin (2 mg/ml), N-acetyl-l-cysteine (63 mg/ml), basic fibroblast factor (1 ng/ml), and B27 (1:50) supplement for 24 h. CM was derived using this DM composition to enable comparison with the control condition for NSC, which was DM alone. CM was then recentrifuged twice at 2000 rpm for 2 min and collected for use. The effects of NOD-scid–derived CM on NSC were replicated using CM derived from fully immune-sufficient Sprague–Dawley rats, according to the sodium caseinate method described above (Fig. 1H). Viability and survival of PMN and Mϕ in DM were confirmed by flow cytometry, as described below. To test the dose–response relationship between PMN and Mϕ-CM and cell migration (Fig. 4), isolated PMN and Mϕ were seeded at initial densities ranging from 156,000 to 2,500,000 cells/ml in DM and CM collected as above. Based on NSC migration results with these CM (Fig. 4A, 4B), CM used in all other in vitro migration and fate experiments was derived from an initial seeding density of 2,500,000 PMN or Mϕ per milliliter.
PMN viability analysis by flow cytometry
PMN and Mϕ (2,500,000 cells/ml) viability following CM generation from C57BL/6 mice described above was tested using propidium iodide (PI) incorporation that can be quantified by flow cytometry. A total of 2 μl/ml PI (1 mg/ml; Invitrogen) was added to PMN maintained in culture for 24 h under the conditions used to generate CM. After a 15- to 20-min incubation period at 37°C, CM (containing floating PMN) was collected in a 15-ml tube, and adherent PMN were detached with 500 μl TrypLE (Invitrogen). Collected floating or adherent PMN were combined into a single sample, and the combined collected cell pellet was resuspended in 300 μl PBS and analyzed on a BD LSR II flow cytometer; the analyzed cell pellet therefore included both live and dead PMN. As previously described (25), dead cells were quantified by gating to viable cells that did not receive PI. The mean values of PMN-positive cells for PI were expressed as percentage (±SE relative to PMN that did not receive PI treatment). Data are averaged across three separate experiments (n = 3; Fig. 1A, 1B).
hNSC culture, cell fate, cell death, and proliferation analysis
Multipotent hCNS-derived stem cells (referred to as hNSC from this point forward) were isolated from 16 to 20 wk gestation human fetal brain and propagated as neurospheres (StemCells), as described previously (26). Briefly, hNSC are isolated by prospective sorting for a CD133+/CD34−/CD45−/CD24−/lo population (26, 27), which enriches for NSC that exhibit neurosphere-initiating capacity by 2000-fold. Cells derived in this manner retain multipotent capacity for >10 passages in vitro and differentiate in a site-specific manner upon transplantation, generating neurons, oligodendrocytes, and astrocytes.
To assess the effect of PMN and Mϕ-CM or purified C1q and/or C3a, hNSC at passages 9–11 were dissociated into single cells and plated on eight-well chamber slides. For fate analysis, 1 d postplating, DM was changed to either DM control or CM conditions (see Table I for details). For immunocytochemistry, hNSC were fixed with 2% paraformaldehyde at 7 or 14 d in vitro (DIV), permeabilized, and blocked in PBS solution supplemented with 0.1% Triton X-100 (Sigma-Aldrich), 5% goat or donkey serum (Jackson ImmunoResearch), and 1% BSA (Sigma-Aldrich). Primary and secondary Abs (including glial fibrillary acidic protein [GFAP], Olig2, and β-tubulin III), sources, and the dilutions at which they were used are listed in Table II. Hoechst 33342 (1:1000 dilution; Invitrogen) was used as a nuclear counterstain. Fluorescent images of immunostained slides were captured using random sampling on a FluoViewFV10i confocal microscope using a ×20 objective, and saved as red, blue, and green channels. Images were merged and quantified using Volocity 5.0 software (28). For all experiments using hNSC, n = 8–10 images per condition per experiment and a minimum of three independent experiments was analyzed. When cultures were prepared across a specific timeline, all time points in those experiments were run in parallel for staining and quantification. For assessment of cell death and cell proliferation, hNSC were plated in the conditions described above and fixed at 1, 2, 3, or 7 DIV, and immunocytochemistry was conducted using Abs directed against cleaved caspase-3 (CC3) to assay for cell death, or BrdU (10 μM) to label for BrdU incorporation by proliferating cells (Table II provides list of the Abs). All experiments in which hNSC were used were conducted in biological triplicate or quadruplicate with technical replicates.
Table I. List of conditions used in in vitro fate analysis and chemotactic assay.
Condition | Host Species | Concentration or Dilution Used | Manufacturer | Catalogue Number |
---|---|---|---|---|
Purified C1q (C1q[PMN]) | Human serum | 28 ng/ml | My Biosource | MBS143105 |
Purified C1q (C1q[Mϕ]) | Human serum | 400 ng/ml | My Biosource | MBS143105 |
Purified C3a (C3a[PMN]) | Human | 18.5 ng/ml | Quidel | Component of kit A015, predecessor to A031 |
Purified C3a (C3a[Mϕ]) | Human | 120 ng/ml | Quidel | Component of kit A015, predecessor to A031 |
Purified C3a desArg | Human | 18.5 ng/ml | Complement Technologies | A119 |
SDF1α | Human | 200 ng/ml | PeproTech | 300-28A |
αC1q | Goat anti-human | 20 μg/ml (chemotaxis); 1.65 μg/ml (fate); 100 μg/ml in vivo | Quidel | A301 |
αC3α | Mouse anti-human | 20 μg/ml (chemotaxis); 1.65 μg/ml (fate); 100 μg/ml in vivo | Millipore | CBL191 |
αTNF-α | Rabbit anti–TNF-α | 2 and 6 μg/ml | Millipore | AB2148P |
αSDF1α | Mouse anti-SDF1α | 100 μg/ml | Millipore | MABC184 |
C1q IgG control | Goat IgG | 20 μg/ml in vitro and 2000 μg/ml in vivo | Jackson ImmunoResearch and R&D Systems | 005-000-005 |
C3a IgG control | Mouse IgG | 20 μg/ml in vitro and 2000 μg/ml in vivo | Jackson ImmunoResearch and R&D Systems | 015-000-003 |
LY294002 | N/A | 50 μM dissolved in DMSO | Life Technologies | PHZ1144 |
PD98059 | N/A | 10 μM dissolved in DMSO | Life Technologies | PHZ1164 |
DMSO | N/A | 1:1000 | Sigma-Aldrich | D26650 |
N/A, not available.
Table II. List of Abs used for immunocyto/histochemical analyses and Western blots.
Ab | Host | Dilution of Primary Ab (In Vivo) | Dilution of Primary Ab (In Vitro) | Manufacturer of Primary Ab | Specificity of Primary Ab | Secondary Ab (In Vitro and In Vivo) |
---|---|---|---|---|---|---|
BrdU | Rat | N/A | 1:100 | Serotec | Proliferating cells | Alexa Fluor donkey anti-rat Fab fragment 488 (1:5–10,000) |
β-Tubulin III | Rabbit | 1:5000 | 1:100 | Covance | Neurons | Biotinylated or Alexa Fluor 488–conjugated donkey anti-rabbit Fab fragment (1:5–10,0000) |
CC1 | Mouse | 1:4000 | N/A | Calbiochem | Mature oligodendrocytes | Biotinylated donkey anti-mouse Fab fragment (1:10,000) |
CC3 | Rabbit | N/A | 1:100 | Cell Signaling Technology | Apoptotic cells | Alexa Fluor donkey anti-rabbit IgG 555 (1:5,000) |
Fibronectin | Rabbit | 1:500 | N/A | Sigma-Aldrich | Fibronectin-containing lesion | Biotinylated donkey anti-rabbit Fab fragment (1:10,000) |
GFAP | Rabbit | 1:60,000 | 1:100 | Dako | GFAP-positive astrocytes | Biotinylated or Alexa Fluor 555–conjugated donkey anti-rabbit Fab fragment (1:10,000) |
Olig-2 | Goat | 1:100 | 1:100 | R&D Systems | Oligodendrocyte progenitor cells | Biotinylated or Alexa Fluor 488–conjugated donkey anti-goat Fab fragment (1:10,000) |
SC121 | Mouse | 1:3000 | N/A | StemCells | Human cytoplasm | Biotinylated donkey anti-mouse Fab fragment (1:10,000) |
SC123 | Mouse | 1:3000 | N/A | StemCells | Human-positive astrocytes | Biotinylated donkey anti-mouse Fab fragment (1:10,000) |
Sox2 | Goat | 1:200 | N/A | Santa Cruz Biotechnology | Sox2-positive progenitor cells | Alexa Fluor donkey anti-goat 488 (1:200) |
GAPDH | Rabbit | 1:1000 | N/A | Cell Signaling | Housekeeping | ECL donkey anti-mouse Fab fragment (1:10,000) |
C3 | Goat | 1:200 | N/A | Quidel | Human and mouse C3 | ECL donkey anti-goat IgG, HRP-linked whole Ab (1:10,0000) |
C1q | Goat | 1:200 | N/A | Quidel | Human and mouse C1q | ECL donkey anti-goat IgG, HRP-linked whole Ab (1:10,0000) |
β-Actin | Mouse | 1:1000 | N/A | Sigma-Aldrich | β-actin | ECL donkey anti-mouse IgG, HRP-linked whole Ab (1:10,0000) |
p-ERK | Rabbit | 1:1000 | N/A | Cell Signaling Technology | Phosphorylated ERK | ECL donkey anti-rabbit IgG, HRP-linked whole Ab (1:10,0000) |
p-AKT | Rabbit | 1:1000 | N/A | Cell Signaling Technology | Phosphorylated AKT | ECL donkey anti-rabbit IgG, HRP-linked whole Ab (1:10,0000) |
N/A, not applicable.
Transwell migration assays
hNSC at passages 9–11 were prepared and dissociated as above. Source and concentration of individual proteins, Abs, IgGs, or inhibitors used are indicated in Table I. Single cells were resuspended in DM. One hundred fifty microliters of media for each condition was added to the wells of the feeder tray (Millipore), and 100 μl dissociated hNSC (300,000 cells/ml DM) was added to the migration chambers, followed by incubation for 3.5 h at 37°C. Migration chambers were removed, placed on new 96-well trays containing 150 μl prewarmed cell detachment buffer in the wells, and incubated for 30 min at 37°C. At the end of the incubation, 50 μl 1:75 dilution of CyQuant GR Dye:Lysis buffer was added to the cell detachment buffer and incubated for 15 min at room temperature. Finally, 150 μl CyQuant GR Dye:Lysis/detachment solution was transferred to a new 96-well plate, and migration was quantified using a 480/520-nm filter set on a fluorescent plate reader. To obtain fluorescence standardization, cells of known doses, as well as blanks containing cell detachment buffer, lysis buffer, and CyQuant Dye, were used. All experiments were conducted in biological triplicate or quadruplicate with technical replicates.
Blocking Abs
Abs against C1q and C3a, as well as SDF1α and TNF-α, were employed to test the effect and specificity of complement component blockade on hNSC fate and migration at 7 DIV (Table I). Inhibition of C3a-, SDF1α-, and TNF-α–mediated responses by blocking Abs has been a widely used tool. C3a, SDF1α, and TNF-α blocking Abs were selected based on specificity, for example, lack of cross-reactivity with whole C3, and previously established function-blocking activity in vitro and in vivo (29–31). In the case of anti-C3a, although this Ab has been shown to have cross-reactivity with human, guinea pig, and rabbit C3a, cross-reactivity with mouse has not been previously characterized. Finally, although this Ab is a mouse monoclonal, this does not pose a confounding variable because the Ab was used either in vitro or in vivo in immunodeficient NOD-scid mice, which lack circulating IgG and IgM.
In contrast, there are no previously characterized assays in which C1q plays a similarly defined role in which function-blocking activity of specific Abs has been assessed. A polyclonal anti-C1q Ab was selected based on wide use in previous studies; specificity for C1q from humans, rats, and mice based on immunoblots; and previous characterization in commercially available human clinical ELISAs and immunoaffinity chromatography (32). In all cases, species- and subtype-matched IgG control Abs were confirmed to lack modifying activity (Table I).
RT-PCR
Expression of mRNA for gC1qR and C3aR by hNSC, and SDF1α, neutrophil elastase (ELANE), complement factor B, complement factor D, and complement factor P (properdin) by PMN was assayed by RT-PCR. GAPDH mRNA was assayed in parallel as a housekeeping standard. Briefly, mRNA from hNSC under nondifferentiating conditions was isolated (RNeasy MiniKit; Qiagen), and RT-PCR was performed (OneStep RT-PCR; Qiagen), as follows: 0.25 μg mRNA per condition; 30 min at 50°C; 15 min at 95°C; and 30 repeated cycles of 1 min at 95°C, 1 min at 55°C, 1 min at 72°C, ending with 10 min at 72°C. For C3aR and gC1qR, human primers were selected to investigate receptor expression by human cells. For SDF1α, ELANE, complement factor B, complement factor D, and complement factor P, mouse primers were selected to investigate mRNA synthesis by PMN derived from mice; mouse liver RNA was included as a positive control to validate SDF1α expression detection by this primer set and lack of expression by PMN. A complete list of all primers used is provided in Table III.
Table III. List of primers.
Name of Primer | Forward | Reverse |
---|---|---|
C3aR | 5′-TCGCTGGCTCACTTGGCTCTC-3′ | 5′-CATCCCTACATTGCGATGATT-3′ |
gC1qR | 5′-AGTGCGGAAAGTTGCCGGGGA-3′ | 5′-GAGCTCCACCAGCTCATCTGC-3′ |
SDF1α | 5′-CCATGGACGCCAAGGTCGTC-3′ | 5′-GGGCTGTTGTGCTTACTTGTTT-3′ |
ELANE | 5′-GTGGACACAGTACCGAGGAC-3′ | 5′-CCAGTTGCTTCGGATGAGGG-3′ |
Factor B | 5′-TTCACCCAGTATGAGGAGTCC-3′ | 5′-GCTGACCATTGTGGAGACCT-3′ |
Factor D | 5′-CGGATGACGACTCTGTGCAG-3′ | 5′-TCATACCATCGCTTGTAGGGT-3′ |
Complement factor properdin | 5′-TTCACCCAGTATGAGGAGTCC-3′ | 5′-GCTGACCATTGTGGAGACCT-3′ |
GAPDH (human) | 5′-TGGAAATCCCATCACCATCT-3′ | 5′-GTCTTCTGGGTGGCAGTGAT-3′ |
GAPDH (mouse) | 5′-TGACCTCAACTACATGGTCTACA-3′ | 5′-CTTCCCATTCTCGGCCTTG-3′ |
GAPDH (human) was used in Supplemental Fig. 3, and GAPDH (mouse) was used in Fig. 5 and Fig. 8F′.
ELISAs and C3 cleavage inhibition
C1q concentration in NOD-scid PMN-CM (2,500,000 cells/ml), Mϕ-CM (2,500,000 cells/ml), and DM control media was measured using a human C1q ELISA kit (HK356; Hycult), according to the manufacturer’s instructions. This kit is reported by the manufacturer to cross-react with mouse C1q. C3a concentration in NOD-scid PMN-CM and DM control media was measured initially using a human C3a ELISA kit (A015; Quidel) that has also been shown to recognize mouse C3a (Fig. 5B, 5D). Prior to completion of all studies for this manuscript, Quidel ceased production of A015 and incorporated a different Ab against human C3a in a new ELISA kit (A031), which did not recognize mouse C3a in our experiments. Accordingly, subsequent studies (Fig. 5F, 5G) were completed using a different C3a ELISA kit (A354; Hycult), which recognizes both mouse and human C3a.
Briefly, PMN were collected from NOD-scid mice and plated in DM control, as described above, at 2,500,000 seeding density. To verify active C3 cleavage to C3a, 1 μg/ml C3 or equal volume of DM control was added to cultured PMN, and C3a generation was measured after 24 h of incubation at 37°C (Fig. 5F). To test the mechanism of C3a generation, EDTA, PMSF, DIFP, or equal volume of DM control was added to cultured PMN, and C3a generation was measured in PMN-CM after 24 h of incubation at 37°C (Fig. 5G). The effect of Ca2+/Mg2+ chelation on C3a generation was tested using 1 and 10 mM EDTA. The effect of serine protease inhibition on C3a generation was tested using 0.1 and 0.5 mM PMSF (catalogue P7626; Sigma-Aldrich) or DIFP (catalogue D0879; Sigma-Aldrich). These experiments were conducted in biological triplicate (Fig. 5F, 5G) or biological duplicate with technical replicates or triplicates (Fig. 5A–D).
p-AKT and p-ERK signaling
To assess the induction of hNSC signaling by PMN-CM, NSC were grown in monolayer at 90% confluence, treated either with PMN-CM derived from 3-mo-old C1q KO and C3 KO BUB/BnJ mice and their littermate controls (wild type) or with purified C1q and C3a at the concentrations measured in CM, referred to as C1q plus C3a[PMN] and C1q plus C3a[Mϕ]. PMN-CM was isolated, as described above. hNSC were lysed in RIPA buffer (Sigma-Aldrich) containing protease and phosphatase inhibitor mixture (cOmplete ULTRA Tablets EASYpack, and PhosSTOP; Roche) immediately (0 s), 30 min, 1 h, or 2 h after PMN-CM addition. Protein concentration was determined in precleared extracts using the micro bicinchoninic acid protein assay (Pierce, Rockford, IL) with BSA as standard. Equal amounts of protein were resolved in SDS-PAGE precast 4–12% gradient gels (NuPAGE Bis-Tris Gel; Life Technologies, Carlsbad, CA), transferred onto Nitrocellulose Pre-Cut Blotting Membranes NuPAGE (Life Technologies) in a semiwet chamber Trans-Blot SD Semi-Dry Cell (Bio-Rad, Hercules, CA), and subjected to Western blot analysis. Abs against p-AKT, p-ERK, and β-actin were used for immunodetection. Bound Abs were visualized using HRP-coupled secondary Abs anti-mouse and anti-rabbit, followed by detection of labeled proteins using SuperSignal West Dura ECL kit (Pierce) and ChemiDoc imaging system (Bio-Rad). Optical band intensities in each group were normalized to those visualized using anti–β-actin Ab and compared using ImageJ (National Institutes of Health; https://imagej.nih.gov/nih-image/). All Abs, sources, and dilutions are provided in Table II.
Detection of C1q and C3 at the SCI epicenter
Two-month-old female C57BL/6 mice received either a laminectomy (control; n = 1) or a moderate contusion injury (50 kilodynes; n = 1) at the thoracic level T9, as described below. Twenty-four hours following SCI or laminectomy, the spinal cord was freshly dissected and divided into a 3-mm segment centered at T9, and sequential 3-mm segments extending rostral and caudal from T9. Total protein extraction (RIPA buffer) with protease and phosphatase inhibitors was performed, and complement proteins were analyzed by SDS-PAGE using αC1q- and αC3-specific Abs (C1q Quidel A301; C3 Quidel A304), essentially as described above. GAPDH was used as the loading control in all experiments. Source and dilutions of all Abs are provided under Table II.
Contusion injuries
A total of 22 female NOD-scid mice (10 wk old; Jackson Laboratories) was anesthetized using isofluorane and received a laminectomy at the thoracic vertebrae 9 (T9) using a surgical microscope. Animals received 50 kilodyne (1 dyne = 10 μN) contusion injuries using the Infinite Horizon Impactor (Precision Systems and Instrumentation, Lexington, KY), as previously described (33). As noted above, although NOD-scid mice exhibit deficits in adaptive immunity, they demonstrate innate immune responses and histopathological characteristics comparable to other mouse strains following SCI (23).
Administration of Abs directed against C1q and C3a in vivo
Immediately after injury, 2 μl either αC1q plus αC3a Abs (100 μg/ml each) or IgG Abs (200 μg/ml) or vehicle were delivered via epicenter injections using a Hamilton Flexifil Syringe over 2 min, followed by a 1-min delay prior to withdrawal of syringe. The effect of αC1q plus αC3a Abs at the concentration delivered in vivo was first tested in vitro, and no toxic or proliferative effects associated with exposure of hNSC to the Abs were observed. Animals were randomly assigned to receive either αC1q plus αC3a Ab with hNSC or vehicle injection (media in which Abs were prepared) with hNSC. Number of animals per group and exclusions are detailed in Table IV.
Table IV. Number of animals per group for in vivo studies.
Group | Time of Sacrifice | Plane of Section Cut/Purpose | N | Exclusions |
---|---|---|---|---|
αC1q Ab + αC3a Ab + hNSC | 12 wk posttransplant | Transverse/Fate and lesion quantification | 7 | n = 1 was excluded in fate quantification due to poor immunostaining |
αC1q Ab + αC3a Ab + hNSC | 12 wk posttransplant | Parasagittal/Histology | 2 | None |
αC1q Ab + αC3a Ab + hNSC | 6 wk posttransplant | Parasagittal/Histology | 2 | None |
Vehicle + hNSC | 12 wk posttransplant | Transverse/Fate and lesion quantification | 5 | None |
Vehicle + hNSC | 6 wk posttransplant | Parasagittal/Histology | 5 | None |
Vehicle + hNSC | 12 wk posttransplant | Parasagittal/Histology | 2 | None |
hNSC transplantation
Neurospheres were dissociated into a single-cell suspension and concentrated to a final density of 75,000 cells/μl injection buffer on the day of SCI, and transplants were conducted, as described previously (33). Briefly, siliconized beveled glass pipettes (bevel: inner diameter = 70 μm, outer diameter = 100–110 μm; Sutter Instruments, Novato, CA) were loaded with freshly triturated hNSC or injection buffer, and injections were made into the intact parenchyma (two sites bilaterally above and below the injury epicenter) at T9 using a NanoInjector system and micropositioner (WPI Instruments, Waltham, MA) immediately after αC1q plus αC3a Abs or vehicle injection. Each site received 250 nl cells or vehicle, delivered in 50 nl vol over 75 s, followed by a 2-min delay before withdrawal of the pipette (34). Previous studies in our laboratory have demonstrated that this volume does not exacerbate damage to the spinal cord.
After the completion of both αC1q plus αC3a Abs or vehicle injection and hNSC transplants, a small piece of gel foam was placed over the site of laminectomy and the musculature was sutured with chromic gut. Animals received lactated ringers (50 ml/kg) s.c. immediately after surgery and for 3–5 d postsurgery, as well as buprenorphine (0.5 mg/kg s.c.) immediately after injury and for 2 d thereafter. Antibiotics were administered daily until sacrifice, rotating the use of baytril, ciproflaxacin, and ampicillin every 2 wk (2.5 mg/kg dose for all drugs; s.c. delivery for baytril and dissolved in drinking water for ciproflaxacin and ampicillin).
Perfusions and tissue collection
Mice were anesthetized at 6 or 12 wk postinjury and transcardially perfused with PBS, followed by 4% paraformaldehyde. Spinal cord regions corresponding to dorsal roots at T2–T5, T6–T12, and T13-L2 were postfixed overnight in 4% paraformaldehyde, flash frozen at −65°C in isopentane, and stored at −80°C. Number of animals per group and exclusions are detailed in Table IV.
Spinal cord immunohistochemistry
The T6–T12 spinal cord region was frozen in isopentane at −55°C and embedded in optimal cutting temperature compound (OCT; Tissue-Tek). Thirty-micrometer–thick parasagittal sections were cut on a freezing microtome, or 30-μm–thick transverse sections were cut using a CryoJane tape transfer system (Leica), as previously described (35, 36). Number of animals cut for each plane is detailed in Table IV. Free-floating sections cut on the microtome were collected in 96-well plates filled with Tris and 0.02% sodium azide and stored at 4°C until processed for immunostaining. CryoJane-cut sections were collected on slides and stored at −20°C until processed for immunostaining. All sectioning and immunostaining procedures were conducted, as previously described (35, 36). Abs and dilutions used are listed in Table II.
Stereological quantification
Cell counts.
The Optical Fractionator probe (37) was used for unbiased estimation of the number of hNSC (SC121+), human astrocytes (SC123+), human Olig-2+ cells (SC121+/Olig2+), and human CC1+ cells (SC121+/CC1+) in StereoInvestigator (Microbrightfield). For the number of SC121+ cells, counting areas were determined by drawing contours at every 1-mm region in parasagittal sections using a ×4 objective and at a frequency of one every sixth section. For fate analysis, the counting areas were determined by drawing contours around the entire transverse spinal cord using a ×4 objective and at the frequency of one every 12th section. Cells associated with a visible nucleus indicated by either methyl green (SC121) or hematoxylin (all other fate markers) were counted using a ×100 objective in the corresponding areas. Grid size measurements were determined based on preliminary experimentation to establish a low coefficient of error (CE) (Table V) and sufficient total estimated counts per frame (3–5 cells per counting frame). hNSC migration was reported as the total number of cells within a 1-mm region.
Table V. CE values for stereological quantification in vivo.
Marker | Group | CE Value |
---|---|---|
SC121 | Vehicle; Ab group | 0.04; 0.04 |
SC123 | Vehicle; Ab group | 0.10; 0.11 |
CC1 | Vehicle; Ab group | 0.12; 0.14 |
Olig-2 | Vehicle; Ab group | 0.07; 0.08 |
Lesion volume analysis.
Lesion volume analysis was performed using fibronectin immunostaining to identify the SCI epicenter in transverse sections and using the Cavalieri estimator probe in StereoInvestigator. The fibronectin-positive region was identified as the lesion epicenter, and a point grid of known spacing (100 μm apart) was randomly overlayed on the section image. Points were counted using a ×20 objective within the region of interest.
Statistical analysis
All analyses were performed by observers blinded to experimental groups. Statistics were performed using Prism 5, version 5.0 (GraphPad Software). All data are presented as mean ± SEM. When percentages are reported, experimental values were normalized to the control condition (DM control). Data were analyzed using one-sample t tests to compare with control and Student t tests to compare between experimental conditions. When comparing across multiple groups, one-way ANOVA was conducted first, followed by Tukey post hoc tests. In Fig. 2, to compare across multiple time points and multiple groups, two-way ANOVA was conducted, followed by a Bonferroni post hoc t test. In all statistical analyses, significance was defined as p < 0.05.
Results
CM collected from PMN, but not Mϕ, promotes astroglial differentiation of hNSC
We sought to investigate whether factors generated by innate immune cells could alter hNSC fate and migration in vitro. Details related to both in vitro and in vivo experiments are outlined in Tables I–V. hNSC were cultured with either DM control or CM collected from PMN or Mϕ. We first confirmed that the culture conditions used for CM generation did not lead to significant or differential cell death in PMN or Mϕ. The number of PI+ PMN and Mϕ was quantified using flow cytometry after 24 h of incubation in DM control (Fig. 1A, Materials and Methods). An average of 6.04% PMN and 5.27% Mϕ were PI+ (Fig. 1B; no significant differences), suggesting a negligible contribution of death/debris to CM collected. hNSC fate was analyzed by quantification of the number of cells immunolabeled for GFAP (astroglial lineage), nuclear Olig2 (oligodendroglial lineage), and β-tubulin III (neuronal lineage). To confirm the relationship of GFAP expression with astroglial lineage commitment as opposed to maintenance of neural progenitors, we evaluated GFAP in combination with the stem cell markers Nestin and Sox2. Quantitative RT-PCR revealed that GFAP mRNA expression increased with time under differentiation conditions, whereas Nestin mRNA expression did not (Materials and Methods and data under Fig. 1C, 1D). In parallel, coimmunolabeling of hNSC for GFAP and Sox2 demonstrated that the number of GFAP+/Sox2+ human neural progenitors under differentiation conditions was <0.284% at 14 DIV (Table VI), suggesting that, by this time point, human cells expressing GFAP are committed to the astroglial lineage.
Table VI. GFAP is a reliable marker for hNSC astroglial lineage commitment under differentiation conditions in vitro.
Marker | Percent | SEM, % |
---|---|---|
GFAP+/Sox2− | 19.35 | 4.79 |
GFAP+/Sox2+ | 0.284 | 0.14 |
GFAP−/Sox2+ | 19.15 | 3.8 |
hNPCs were cultured for 14 DIV and immunostained for GFAP and Sox2. Quantification of GFAP+/Sox2+ cell number revealed only 0.28% cells coexpressing these markers after 14 DIV. n = 3 images per well; n = 1 biological replicate. Mean ± SEM.
At 14 DIV, PMN-CM, but not Mϕ-CM, significantly increased the percentage of GFAP+ cells in comparison with DM control (Fig. 1E). Morphologically, PMN-CM exposure resulted in intensely stained GFAP+ cells with extended processes consistent with hypertrophic, reactive astrocytes. In contrast, both PMN-CM and Mϕ-CM decreased the percentage of Olig2+ cells compared with DM control (Fig. 1F), whereas PMN-CM decreased and Mϕ-CM increased the percentage of β-tubulin III+ cells over DM control (Fig. 1G). As described under Materials and Methods, all in vitro experiments (Figs. 1–8) were conducted with PMN-CM generated from NOD-scid mice to enable comparison with in vivo xenotransplantation data in NOD-scid mice (Figs. 9, 10). To confirm that the effect of CM on hNSC fate generalized across species as well as to fully immune-sufficient animals, we generated CM generated from Sprague–Dawley rats and verified a parallel astroglial fate shift (Fig. 1H). Taken together, these data suggest that PMN-CM selectively modulates NSC fate.
PMN-mediated increase in GFAP+ cell proportion in differentiating hNSC could be attributed to either increased astroglial lineage selection or increased death of neuronal or oligodendroglial cells. Given that cell cycle exit and differentiation are linked (38), cell proliferation and death were assessed using BrdU incorporation and CC3 staining, respectively. PMN-CM exposure under differentiating conditions transiently decreased the percentage of hNSC exhibiting BrdU incorporation at 1 DIV and 3 DIV, but not at 7 DIV when compared with DM control (Fig. 2A–C). Early decreases in BrdU incorporation were not associated with increased CC3+ cell proportion (Fig. 2D–F), consistent with the induction of differentiation and not cell death. These data suggest that PMN-CM selectively accelerates hNSC differentiation and promotes astroglial lineage selection.
If PMN-CM promotes astroglial lineage selection, we would predict the kinetics of differentiation to demonstrate a steady increase in the proportion of GFAP+ human cells over time, with a corresponding decrease in the proportion of nuclear Olig2+ and/or β-tubulin III+ cells. We quantified the number of GFAP+, nuclear Olig2+, and β-tubulin III+ cells following hNSC exposure to PMN-CM or DM control at 7 versus 14 DIV, as described above. Consistent with a lineage selection mechanism, the percentage of GFAP+ cells increased (Fig. 3A), the percentage of oligodendroglial cells decreased (Fig. 3B), and percentage of neuronal cells remained the same over time (Fig. 3C). A parallel question is whether continuous exposure to PMN-CM throughout the period of differentiation is required, or whether a transient priming or conditioning exposure is sufficient. This is important for in vivo relevance, as PMN infiltration is often transient, including after CNS injury. To test this, hNSC were exposed to PMN-CM or DM control for 24 h, washed, and followed by a 13 DIV incubation in DM. Transient PMN-CM exposure also resulted in an increase in the percentage of GFAP+ cells compared with DM control (Fig. 3D). Taken together, these data suggest that PMN-CM selectively directs NSC differentiation toward an astroglial lineage, and that a transient or priming exposure to factors present in PMN-CM is sufficient to drive lineage commitment.
CM collected from PMN, but not Mϕ, promotes hNSC migration
Innate immune cells synthesize a variety of chemotactic factors that can affect NSC/NPC migration, for example, TNF-α and IFN-γ (39). Microglial-directed NSC migration has been previously demonstrated (15), but the effect of PMN and Mϕ on NSC chemotaxis, and the role of specific factors in these effects, has not been tested. We investigated the effect of PMN-CM and Mϕ-CM on hNSC migration using Transwell (Boyden chamber) chemotactic assays. Transwell assays permit directional assessment of migration if conducted over a short timescale (hours) before concentration differences for the molecule(s) of interest equalize between the upper and lower compartments. However, Transwell assays do not permit evaluation of migration over a linear chemotactic gradient; accordingly, evaluation across an increasing concentration series is used to demonstrate that any observed effects are not the result of random motion (chemokinesis) (40). Using a set incubation period of 3.5 h, we therefore tested this relationship using CM generated from different initial seeding densities (156,000 to 2,500,000 cells/ml) of PMN and Mϕ, and harvesting CM, as described under Materials and Methods.
PMN-CM induced a seeding density-dependent increase in hNSC migration (Fig. 4A), suggesting the synthesis of chemotactic factors by PMN. In contrast, Mϕ-CM did not affect hNSC migration even in CM generated from the highest seeding density (Fig. 4B). Direct comparison of 2,500,000 PMN-CM and Mϕ-CM demonstrated a significant increase in hNSC migration in response to PMN-CM and the chemoattractant SDF1α (CXCL12; 200 ng/ml) (41), but not Mϕ-CM (Fig. 4C). SDF1α is a migration signal for many cell types during both development and adulthood (42); neural progenitor cells have been shown to express the SDF1α receptor, CXCR4, as well as to exhibit migration in vitro and in vivo in response to SDF1α (43, 44). Accordingly, SDF1α was employed as a positive migration control. Previous studies have shown that hNSC chemotaxis approaches an active threshold at 100 ng/ml and the chemotactic index remains stable for SDF1α concentrations between 100 and 1000 ng/ml (41). In the current study, the chemotactic response of hNSC to PMN-CM was 1.5 times greater than SDF1α at 200 ng/ml (209.5 versus 134.2%, respectively), suggesting that the soluble factors present in PMN-CM exert a robust and strong effect on hNSC migration. Furthermore, the absence of an enhanced chemotactic response to Mϕ-CM suggests either that soluble factors specific to PMN-CM induce migration, or that hNSC migration is modulated in a dose-dependent manner by factors present at different concentrations in PMN-CM versus Mϕ-CM.
PMN- and Mϕ-CM factors
PMN and Mϕ synthesize multiple cytokines and chemokines, including TNF-α (24, 45, 46). As well, we and others have shown that some components of the complement cascade, specifically C1q and C3, are synthesized by PMN and Mϕ both in vitro and in vivo following neurodegeneration (47–49). Both C1q and C3a, a cleavage product of C3, have been reported to direct cell migration (49–51). Additionally, C3a has been reported to modulate neurogenesis and neuronal fate in mouse neural progenitors (52). We hypothesized that one or more of these components could modulate NSC fate and migration.
To test this hypothesis, we first established the concentrations of C1q and C3a in CM via ELISAs (Fig. 5A–D). Mϕ-CM contained significantly higher concentrations of both C1q and C3a (Fig 5B, 5D; 400 and 120 ng/ml, respectively) compared with PMN-CM (Fig 5A, 5C; 28 and 18.5 ng/ml, respectively). To identify whether interaction between PMN/Mϕ-generated C1q/C3a and hNSC was possible, we verified the expression of the gC1qR and C3aR by hNSC via PCR (Supplemental Fig. 1A). In parallel, we tested whether treatment of hNSC with CM induces signaling pathway activation that is dependent upon the presence of complement proteins. Phosphoarray analysis of intracellular signaling pathways identified p-AKT and p-ERK as strongly activated after treatment of hNSC with C1q and C3a. Quantification of p-AKT and p-ERK in immunoblots from hNSC treated with PMN-CM generated from wild-type, C1qKO, or C3KO mice showed that activation of p-AKT signaling was blocked in both C1qKO and C3KO PMN-CM, whereas activation of p-ERK signaling was blocked in C3KO but not C1qKO PMN-CM (Supplemental Fig. 1B–D). Altogether, these data suggest that C1q and C3a play a role in PMN-CM–induced signaling pathway activation in hNSC.
Critically, C3 must be cleaved to generate active C3a. Proteolytic cleavage of C3 to C3a and other C3 fragments can occur via the classical and alternative complement pathways and their C3 convertases, which are Ca2+/Mg2+ dependent. PMN synthesize and secrete factor B as well as factor D (Fig. 5E), which are required for C3(H20)Bb and fC3bFb alternative pathway convertase formation (50, 51, 53, 54). This process can be triggered spontaneously, via generation of C3(H20) in the fluid phase. Critically, although C3bBb is more active than C3(H20)Bb, generating 2-fold the amount of C3a, factor B has a greater affinity for C3(H20), and the resistance of C3(H20)Bb to inactivation results in prolonged activity (55). PMN also synthesize and secrete properdin (Fig. 5E), which, in combination with C3b membrane binding, amplifies convertase activity and C3a generation (54, 56, 57). Additionally, C3 can undergo direct cleavage by neutral and serine proteases, generating C3a (58, 59). Finally, PMN secrete elastases (e.g., ELANE, Fig. 5E), and ELANE efficiently cleaves C3 into biologically active C3a (59). To test for fluid-phase C3a generation, purified C3 was added to cultured PMN in vitro and C3a measured by ELISA in PMN-CM. C3 addition to PMN increased C3a in PMN-CM (Fig. 5F). Conversely, addition of either the divalent cation chelator EDTA or protease inhibitors (DIFP or PMSF) to cultured PMN decreased C3a in PMN-CM in a dose-dependent manner (Fig. 5G). These data are consistent with early demonstrations of PMN-derived cationic and neutral protease C3 cleavage and C3a generation (60, 61), as well as recent studies of ELANE C3 cleavage and C3a generation (59). Critically, in this regard, inhibition of C3a generation by EDTA in our data does not necessarily reflect C3 convertase inhibition, as EDTA has been shown to bind and inhibit ELANE (62). Collectively, these data suggest that PMN-CM not only contains C3a, but can process C3 to generate C3a.
Based on these data, we investigated the role of C1q and C3a in the modulation of hNSC fate and migration using two approaches (Fig. 5H): 1) addition of exogenous purified C1q and/or C3a alone or in combination to DM control conditions, that is, in the absence of PMN-CM or Mϕ-CM, and 2) addition of Abs directed against C1q and/or C3a alone or in combination to PMN-CM or DM control conditions.
Addition of purified C1q and/or C3a modulates p-AKT/p-ERK signaling, hNSC fate, and hNSC migration
For the first approach, hNSC were cultured with either DM control or DM with the addition of purified C1q and/or C3a at the concentrations measured in CM, referred to as C1q plus C3a[PMN] and C1q plus C3a[Mϕ]. The effect of purified C1q plus C3a[PMN] and C1q plus C3a[Mϕ] on p-AKT and p-ERK signaling was verified, as described above, supporting the activity of these molecules independent of other CM components (Supplemental Fig. 1E, 1F). hNSC fate was analyzed by quantification of the number of cells immunolabeled for GFAP, nuclear Olig2, and β-tubulin III after 14 DIV, as shown above in Fig. 1E–G. Both C1q and C3a exhibited independent effects on hNSC differentiation. For example, C1q[PMN] decreased the percentage of GFAP+ cells only (Fig. 6A), whereas treatment with C1q[Mϕ] decreased the percentage of GFAP+ cells, increased Olig2+ cells, and did not alter β-tubulin III expression at 14 DIV (Fig. 6B). With respect to C3a, C3a[PMN] did not alter the percentage of GFAP+, Olig2+, or β-tubulin III+ cells identified (Fig. 6A). Conversely, treatment with C3a[Mϕ] decreased the percentage of cells exhibiting GFAP, Olig2, and β-tubulin III expression at 14 DIV (Fig. 6B). These effects were not related to cell death, as there were no increases in the number of CC3+ cells across treatment conditions (Table VII). Critically, however, combined addition of C1q plus C3a is most relevant for comparison with CM treatment in which both C1q and C3a are present. C1q plus C3a[PMN] increased the percentage of GFAP+ cells, whereas C1q plus C3a[Mϕ] did not (Fig. 6A, 6B, Supplemental Fig. 2A). Additionally, both C1q plus C3a[PMN] and C1q plus C3a[Mϕ] resulted in a significant decrease in the percentage of Olig2+ hNSC compared with control (Fig. 6A, 6B, Supplemental Fig. 2B). These effects are consistent with those observed when hNSC were differentiated in PMN- and Mϕ-CM (Fig. 1). However, neither C1q plus C3a[PMN] nor C1q plus C3a[Mϕ] altered the percentage of β-tubulin III+ hNSC (Fig. 6A, 6B, Supplemental Fig. 2C), suggesting that factors other than C1q and C3a mediate the effect of CM on this aspect of hNSC fate. Critically, addition of purified C3a-desArg to hNSC did not alter cell fate with respect to GFAP, Olig2, or β-tubulin III+ cells (Supplemental Fig. 2D), and mRNA for C5L2, one of the known receptors for C3a-desArg, was not detected in hNSC samples (Supplemental Fig. 2E). These data demonstrate that the effects of C3a in this in vitro study cannot be attributed to C3a-desArg. Collectively, it can be concluded that C1q and C3a exert specific, concentration-dependent effects on hNSC and may operate interactively to modulate hNSC differentiation.
Table VII. CC3 analysis at 48 h in vitro.
Condition | Number of CC3+ Cells | N | Statistics |
---|---|---|---|
C1q at [PMN] | 0.200 ± 0.891 | 4 | NS |
C1q at [Mϕ] | 0.222 ± 0.084 | 4 | NS |
Control for C1q | 0.139 ± 0.066 | 4 | N/A |
C3a at [PMN] | 0.125 ± 0.063 | 4 | Significant decrease compared with control; p < 0.05 |
C3a at [Mϕ] | 0.308 ± 0.105 | 3 | NS |
Control for C3a | 0.303 ± 0.072 | 7 | N/A |
C1q + C3a at [PMN] | 0.322 ± 0.137 | 3 | NS |
C1q + C3a at [Mϕ] | 0.234 ± 0.116 | 3 | NS |
Control for C1q + C3a | 0.234 ± 0.116 | 3 | N/A |
N are indicated, and 10 random images were quantified per N. Mean ± SEM is shown. Statistical analyses were conducted using Student t test to compare with control for each condition. Significance is p < 0.05.
N/A, not applicable.
In parallel with hNSC fate, the effect of purified C1q and/or C3a on hNSC migration was tested using Transwell chemotactic assays, as described above, for PMN-CM and Mϕ-CM. SDF1α (200 ng/ml) was included as a positive control in all migration experiments, as above (black bars, Fig. 6C, 6D). hNSC exhibited increased migration toward C1q[PMN], C3a[PMN], and C1q plus C3a[PMN] compared with both DM control and SDF1α (Fig. 6C). In contrast, addition of C1q plus C3a[Mϕ] significantly decreased hNSC migration compared with DM control and SDF1α (Fig. 6D), suggesting a repulsive effect. Interestingly, concentration-dependent chemoattraction versus chemorepulsion (fugetaxis) is consistent with previous reports for PMN and T cell responses to IL-8 and SDF1α gradients in vitro and in vivo (63, 64). In particular, higher concentrations of IL-8 and greater CXCR2 occupancy in human PMN were associated with conversion from chemoattraction to chemorepulsion (63); moreover, both chemoattraction and chemorepulsion were sensitive to PI3K/AKT inhibitors. These findings parallel our observations of PI3K/AKT activation by C1q plus C3a[PMN] and C1q plus C3a[Mϕ], and are consistent with reports by Tharp et al. (63) that chemorepulsion control lies downstream of PI3K/AKT.
As a test of the biological activity of signaling induced by purified C1q and C3a on hNSC, we assayed the effects of PMN-CM and C1q plus C3a[PMN] on hNSC in the presence and absence of PI3K/AKT and ERK pathway inhibitors (LY294002 and PD98059, respectively), and used hNSC migration as a functional readout in which cellular toxicity is minimized due to the short-term incubation. hNSC migration induced by PMN-CM (Fig. 7A) was significantly attenuated by both PI3K/AKT and ERK pathway inhibition (one-way ANOVA, p < 0.0001, F = 36.72, followed by post hoc Tukey test: p < 0.0001 for PMN-CM versus LY294002, p < 0.0001 for PMN-CM versus PD98059), although a small but significant increase over control remained (one-sample t test: p < 0.001 for LY294002 versus control, p < 0.05 for PD98059 versus control). In parallel, hNSC migration induced by C1q plus C3a[PMN] (Fig. 7B) was completely blocked by ERK pathway inhibition (one-way ANOVA, p = 0.0222, F = 4.355, followed by Tukey post hoc test: p < 0.05 for C1q plus C3a[PMN] versus PD98059), and a strong trend for blockade was observed with PI3K/AKT pathway inhibition (one-way ANOVA, p < 0.05, F = 4.355, followed by Tukey post hoc test: p > 0.05 for C1q plus C3a[PMN] versus PD98059). In addition, C1q plus C3a[PMN] failed to induce migration versus control in the presence of PI3K/AKT or ERK inhibition (one-sample t test: p > 0.05 for LY294002 versus control, p > 0.05 for PD98059 versus control). Taken together, these data support concentration gradient-dependent effects of complement proteins on hNSC migration and indicate that these effects are mediated by activation of intracellular signaling pathways, suggesting a receptor-mediated mechanism.
Blockade of C1q and C3a in PMN-CM reduces astroglial differentiation and migration
In the second approach, hNSC were cultured in either PMN-CM or PMN-CM with the addition of Abs directed against C1q (αC1q Ab) and/or C3a (αC3a Ab). As described under Materials and Methods, blocking Abs were selected based on previously published studies. hNSC fate analysis was restricted to quantification of the number of cells immunolabeled for GFAP. Addition of αC1q Ab and/or αC3a Ab to PMN-CM under differentiating conditions significantly decreased the percentage of GFAP+ cells compared with PMN-CM alone (Fig. 8A, Supplemental Fig. 2F, 2G). In contrast, addition of IgG control Abs (Table I) to hNSC cultured in PMN-CM (Supplemental Fig. 2H), or addition of αC1q and/or αC3a to hNSC cultured under DM control conditions (Fig. 8B), had no effect. Similarly, we targeted an alternative PMN-secreted candidate, TNF-α, which has been shown to promote astrocytic differentiation in vitro (39, 65, 66). αTNF-α Ab treatment of either DM or PMN-CM did not alter GFAP+ fate proportion (Fig. 8C). These data support the specificity of the effects on GFAP+ cell fate observed with αC1q Ab and αC3a Ab treatment, and a novel role for C1q and C3a in hNSC fate.
In parallel with hNSC fate, the effect of αC1q Ab and αC3a Ab treatment on hNSC migration in the presence of PMN-CM was tested using Transwell chemotactic assays. SDF1α (200 ng/ml) was included as a positive control in all migration experiments (black bars, Fig. 8D–F). Addition of αC1q Ab and αC3a Ab to PMN-CM, both individually and in combination, significantly decreased migration compared with PMN-CM alone (Fig. 8D). Addition of αC1q Ab and αC3a Ab to DM control media had no effect on hNSC migration (Fig. 8E). IgG control Abs raised in the same species did not alter migration when added to PMN-CM, supporting the specificity of αC1q Ab– and αC3a Ab–directed blockade (Supplemental Fig. 2I). Additionally, although hNSC are responsive to SDF1α, we found that PMN isolated under our conditions do not express SDF1α mRNA (Fig. 8F). We therefore tested addition of an αSDF1α blocking Ab to PMN-CM as a negative control. As predicted, whereas αSDF1 Ab mitigated SDF1α-induced migration (Fig. 8F, gray bar), addition of αSDF1α Ab to either DM control (Fig. 8F, green bar) or PMN-CM (Fig. 8F, orange bars) had no effect on hNSC migration. Altogether, these data support the specificity of αC1q Ab– and αC3a Ab–directed blockade and demonstrate that C1q and C3a are two key PMN-synthesized molecules modulating hNSC fate and migration.
Treatment with αC1q and αC3a Ab in vivo transiently alters hNSC migration and reduces astroglial fate
Based on these in vitro data, we sought an in vivo parallel. We have previously shown that the time of hNSC transplantation into the parenchyma adjacent to the SCI epicenter is a key variable for the in vivo fate and migration profile of engrafted donor human cells. hNSC in this paradigm are multipotent at the time of transplantation and responsive to migration and fate cues in the local microenvironment. Delayed hNSC transplantation (9–30 d post-SCI) results in donor human cell migration away from the SCI epicenter, toward the distal rostral and caudal spinal cord, and predominant oligodendroglial differentiation (33, 34, 67). Conversely, we have recently demonstrated that acute hNSC transplantation (0 d post-SCI) results in increased donor human cell migration toward the SCI epicenter and a pronounced shift toward astroglial fate in the donor human cells that engraft adjacent to it; critically, both of these effects are blocked by Ly6G-mediated depletion of acute PMN infiltration to the injury epicenter (68).
We therefore sought to test the effect of C1q and C3a blockade using αC1q plus αC3a Ab treatment on hNSC migration and fate in this acute SCI transplantation paradigm. We predicted that administration of αC1q plus αC3a Ab at the SCI epicenter would block recruitment of hNSC toward the SCI epicenter, increasing migration toward the rostral and caudal spinal cord, and reduce the astroglial fate shift of donor hNSC. We first verified that C1q and C3 cleavage products are present at the SCI epicenter during the acute period using SDS-PAGE and immunoblotting in 3-mm segments extending rostral and caudal from the lesion (Supplemental Fig. 3). In vivo studies were conducted in NOD-scid mice to enable survival of donor human cells, as described previously (33, 34, 67, 68) and under Materials and Methods. Importantly, although NOD-scid mice exhibit deficits in adaptive immunity, they demonstrate innate immune responses and histopathological characteristics comparable to other mouse strains following SCI (22, 23).
hNSC were transplanted into the intact parenchyma of NOD-scid mice adjacent to the SCI epicenter immediately after a moderate contusion injury, as previously described (33, 34, 67, 68). Mice received a single epicenter injection of either vehicle or αC1q plus αC3a Abs at the time of transplantation. We confirmed that administration of αC1q plus αC3a Ab did not alter total hNSC engraftment or SCI lesion volume. Quantification was performed by unbiased stereological analysis of immunohistochemistry for the human specific cytoplasmic marker SC121 with the optical fractionator probe, and of immunohistochemistry for firbronectin as a marker for lesion volume with the Cavalieri probe. There were no differences in either the total number of hNSC (Supplemental Fig. 4A, 4B), or fibronectin+ lesion volume (Supplemental Fig. 4C, 4D) in transplanted mice receiving vehicle versus αC1q plus αC3a Ab. Acute injection of IgG control Abs also did not alter the average lesion volume (Student two-tailed t test, p > 0.05).
Migration of engrafted hNSC was assessed histologically at 6 wk posttransplantation, and histologically and quantitatively via analysis of hNSC stereological engraftment data for SC121+ cells at 12 wk posttransplant. At 6 wk posttransplant, histological analyses suggested increased hNSC migration away from the epicenter (Fig. 9A, 9B); however, this effect was not sustained at 12 wk (Fig. 9C–E). These data suggest that the effect of complement blockade on hNSC migration was transient, or that a single epicenter injection of these Abs was insufficient.
Fate of engrafted hNSC was assessed quantitatively 12 wk posttransplantation. Quantification was performed by unbiased stereological analysis of immunohistochemistry for the human specific astroglial marker SC123, colabeling for SC121 and the oligoprogenitor marker nuclear Olig2, and colabeling for SC121 and the mature oligodendroglial marker CC1, using the optical fractionator probe. There was a significant decrease in the number of SC123+ cells (hAstrocytes) in αC1q plus αC3a Ab–treated animals (Fig. 10A, 10D). The number of nuclear Olig2+ human oligoprogenitors (hOlig2+ cells) also decreased in αC1q plus αC3a Ab–treated animals (Fig. 10B, 10E); however, the number of CC1+ human oligodendrocytes (hCC1+ cells) did not change (Fig. 10C, 10F), suggesting the absence of a net effect on mature oligodendroglial numbers. In vehicle-treated mice, hAstrocytes, hOlig2, and hCC1+ cells accounted for 100% of engrafted hNSC; in contrast, in αC1q plus αC3a Ab–treated mice, these markers accounted for only 84% of engrafted hNSC (Fig. 10G), suggesting an increase in either other markers or the undifferentiated human donor cell population. Although a caveat with respect to the effect of αC1q plus αC3a Ab administration in vivo is that neutralizing Ab injection could also have altered leukocyte infiltration or other factors, for example, PMN number or density at the SCI epicenter, these data demonstrate a striking effect of a single injection of αC1q plus αC3a Abs on early hNSC migration in combination with a sustained effect on fate. Accordingly, the collective data provide an in vivo parallel for the effect of complement blockade on hNSC fate.
Discussion
This study identifies a novel and important role for cellular and molecular components of the innate immune response in hNSC fate and migration. We demonstrate that PMN-CM induces hNSC astrogliogenesis and promotes hNSC migration, that these effects are replicated by administration of purified C1q and C3a, and that these effects are blocked by Abs directed against these proteins. Furthermore, proof-of-concept data support an in vivo parallel, as a single acute injection of αC1q plus αC3a Ab into the SCI epicenter transiently inhibited hNSC migration toward the lesion and reduced astroglial differentiation of donor human cells in this paradigm.
C1q circulates in plasma predominantly in C1 complex with the proenzymes C1r and C1s (69). However, C1q can be synthesized in the absence of C1r and C1s by a variety of cell types, including PMN (47, 70, 71). Furthermore, a large body of evidence has shown upregulation of C1q in the CNS following injury/disease/aging (72–74), suggesting that C1q alone may have nontraditional functions (75, 76). In contrast, all known functions of C3 are mediated by its cleavage products, C3b and C3a. C3b is involved in opsonization as well as C5 convertase and membrane attack complex (C5b-9) formation, whereas C3a is an anaphylatoxin with potent chemotactic activity through the C3aR. C3a expression has been associated with basal and ischemia-induced hippocampal neurogenesis (52, 77) as well as SDF1α-induced migration and neuronal differentiation of rodent NPC (78). Once formed, C3a is rapidly cleaved by one or more carboxypeptidases (including N, R, and B) to form C3a-desArg (79). Many cells can synthesize and secrete carboxypeptidases, including neurons, which have been shown to produce carboxypeptidase B. However, we demonstrate that the hNSC tested in this work neither express the putative C3a-desArg receptor C5L2, nor exhibit a response to purified C3a-desArg, supporting a primary role for C3a. Critically, however, although we demonstrate that hNSC express gC1qR and C3aR mRNA, C1q and C3a could interact with other receptors. Further investigations to define the interactions of C1q, C3a, and C3a-desArg, as well as the receptors mediating their effects on NSC fate and migration, are in progress. However, our collective data demonstrate novel alternative functions of both C1q and C3a on CNS cells.
C1q and C3a appear to account for the majority of fate- and migration-modulating activity in PMN-CM, because administration of blocking Abs returned hNSC astroglial differentiation to control levels and prevented ∼76% of the hNSC chemotactic response. Surprisingly, a well-characterized TNF-α function-blocking Ab (30) had no effect, although TNF-α is not only produced by PMN, but has also been shown to mediate astroglial differentiation in vitro (39, 65, 66), and TNF-α–induced STAT3 signaling has been shown to be important for astroglial differentiation of neural progenitors (80, 81). These data could reflect a lack of TNF-α receptor expression in this hNSC population, or developmental regulation of TNFR1/2 expression in neural stem versus progenitor cells (82). Future studies will further investigate the possible signaling mechanisms mediating the specific effect of complement-mediated astrogliogenesis in hNSC.
Addition of purified C1q plus C3a[PMN] to DM increased GFAP+ cell fate and migration relative to DM control, as well as relative to C1q plus C3a[Mϕ]. However, the magnitude of this effect in response to purified C1q and C3a was less than that observed with CM. It is possible that purified C1q and C3a are less stable in vitro, and therefore exert a reduced biological effect. Alternatively, despite the lack of effect of αC1q and αC3a blocking Abs in DM control conditions and IgG control Abs in the presence of PMN-CM, we cannot exclude the possibility that αC1q and αC3a acted with other factors in PMN-CM to produce their effects. Ultimately, however, both blockade of complement proteins in PMN-CM and addition of purified ligands at PMN-synthesized concentration yield the same effect with respect to both astroglial differentiation and cell migration, highlighting a role for C1q and C3a in these processes.
We demonstrate significantly higher concentrations of Mϕ- versus PMN-derived C1q and C3a (a 14-fold and 6-fold difference, respectively). We also show that C1q plus C3a[Mϕ] did not alter the percentage of GFAP+ cells compared with control. Furthermore, significantly fewer hNSC migrated toward this high concentration mixture of C1q and C3a compared with control, suggesting a repulsive effect. These data suggest that complement-mediated effects on fate and migration profiles of hNSC are concentration dependent. Although in some ways surprising, this observation is consistent with other literature in the field. For example, in vitro and in vivo studies have shown that increasing the concentration of SDF1α increases cell migration in a linear manner up to a saturation point, after which increasing concentration exerts a chemorepulsive effect (termed fugetaxis) (63, 64, 83, 84). Interestingly, monocytes secrete differential concentrations of both C1q and C3a proteins in an activation state–dependent manner (48, 49, 85, 86), suggesting there may be concentration-dependent physiological roles for these proteins. Identification and characterization of M1 versus M2 Mϕ subpopulations have recently come under fire (87–89), and discrimination between these two subtypes was not within the scope of the current study; however, we can speculate that, in parallel with differences between PMN and Mϕ C1q and C3a generation, variations in Mϕ activation state could also play a role in modulating neural stem and progenitor fate and migration. Moreover, the more complex inflammatory milieu in the developing, injured, or diseased CNS in vivo may further modulate neural stem and progenitor responses to these and other cues.
In the present experiments, hNSC fate profile was assessed in vitro using three principal markers of GFAP, β-tubulin III, and Olig2. Specifically, with respect to GFAP, previous studies have shown heterogeneity in both maturity and marker expression in cultures of human stem cell–derived astrocytes, but identify GFAP expression as a marker for astroglial identity (90), and GFAP is commonly used to characterize astroglial differentiation in hNSC cultures (91–93). Critically, more mature astroglial markers such as GLAST and ALDH1L1 are absent in human cell cultures <4 wk old (90). Additionally, our data are consistent with previous studies demonstrating the progressive loss of Nestin in NSC during differentiation in vitro, and the progressive upregulation of GFAP in a subpopulation of NSC that differentiate into astrocytes (94, 95).
In sum, we demonstrate a novel mechanism by which PMN and Mϕ modulate hNSC fate and migration. Although high concentrations of C3a have been previously shown to affect fate and migration of neural progenitors in the presence of SDF1α (78), our data identify complement proteins as a discrete mechanism by which PMN and Mϕ affect hNSC. Additionally, the current study suggests that this mechanism applies to a broader in vivo setting, in which endogenous and transplanted NSC are present in a microenvironment that contains inflammatory factors and/or cells, such as the developing, diseased, or injured CNS. In SCI, this inflammatory microenvironment has distinct temporal stages and a changing spatial distribution over the acute to chronic postinjury period (3–7). Accordingly, we suggest that understanding the cross-talk between transplanted cells and neuroinflammatory molecules may be critical for predicting the effects of local cues on donor cell properties, and for enhancing the repair or restoration of function by donor cells.
Supplementary Material
Acknowledgments
We thank Robert Tushinski and Dongping He at StemCells Inc. for technical support in maintenance of the human cells. We thank our undergraduates, Brian Ahn and Daniel Cantu, for contributions to immunostaining and quantification.
This work was supported by National Institutes of Health Grant NS49885 (to A.J.A.), California Institute for Regenerative Medicine Grant RS1-00377-1 (to B.J.C.), Paralysis Project of America Grant PPA-32574 (to H.X.N.), California Institute for Regenerative Medicine Stem Cell Training Award T1-00008 (to H.X.N.), Christopher and Dana Reeve Foundation Grant CRF-AAC 2005 (to A.J.A.), and StemCells Inc.
The online version of this article contains supplemental material.
- CC3
- cleaved caspase-3
- CE
- coefficient of error
- CM
- conditioned medium
- DIV
- day in vitro
- DM
- differentiation medium
- ELANE
- neutrophil elastase
- GFAP
- glial fibrillary acidic protein
- hNSC
- human NSC
- KO
- knockout
- Mϕ
- macrophage
- NPC
- neural progenitor/precursor cell
- NSC
- neural stem cell
- PI
- propidium iodide
- PMN
- polymorphonuclear leukocyte
- SCI
- spinal cord injury.
Disclosures
Nobuko Uchida has financial interest in StemCells Inc. The remaining authors have no financial conflicts of interest.
References
- 1.Shihabuddin L. S., Horner P. J., Ray J., Gage F. H. 2000. Adult spinal cord stem cells generate neurons after transplantation in the adult dentate gyrus. J. Neurosci. 20: 8727–8735. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wurmser A. E., Palmer T. D., Gage F. H. 2004. Neuroscience: cellular interactions in the stem cell niche. Science 304: 1253–1255. [DOI] [PubMed] [Google Scholar]
- 3.Popovich P. G., Wei P., Stokes B. T. 1997. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377: 443–464. [DOI] [PubMed] [Google Scholar]
- 4.Kigerl K. A., McGaughy V. M., Popovich P. G. 2006. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J. Comp. Neurol. 494: 578–594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Jones T. B., McDaniel E. E., Popovich P. G. 2005. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr. Pharm. Des. 11: 1223–1236. [DOI] [PubMed] [Google Scholar]
- 6.Fleming J. C., Norenberg M. D., Ramsay D. A., Dekaban G. A., Marcillo A. E., Saenz A. D., Pasquale-Styles M., Dietrich W. D., Weaver L. C. 2006. The cellular inflammatory response in human spinal cords after injury. Brain 129: 3249–3269. [DOI] [PubMed] [Google Scholar]
- 7.Beck K. D., Nguyen H. X., Galvan M. D., Salazar D. L., Woodruff T. M., Anderson A. J. 2010. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 133: 433–447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhang R., Liu Y., Yan K., Chen L., Chen X. R., Li P., Chen F. F., Jiang X. D. 2013. Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J. Neuroinflammation 10: 106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Butovsky O., Ziv Y., Schwartz A., Landa G., Talpalar A. E., Pluchino S., Martino G., Schwartz M. 2006. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell. Neurosci. 31: 149–160. [DOI] [PubMed] [Google Scholar]
- 10.Pluchino S., Zanotti L., Rossi B., Brambilla E., Ottoboni L., Salani G., Martinello M., Cattalini A., Bergami A., Furlan R., et al. 2005. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436: 266–271. [DOI] [PubMed] [Google Scholar]
- 11.Javorkova E., Trosan P., Zajicova A., Krulova M., Hajkova M., Holan V. 2014. Modulation of the early inflammatory microenvironment in the alkali-burned eye by systemically administered interferon-γ-treated mesenchymal stromal cells. Stem Cells Dev. 23: 2490–2500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tena A., Sachs D. H. 2014. Stem cells: immunology and immunomodulation. Dev. Ophthalmol. 53: 122–132. [DOI] [PubMed] [Google Scholar]
- 13.Ziv Y., Avidan H., Pluchino S., Martino G., Schwartz M. 2006. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. [Published erratum appears in 2006 Proc. Natl. Acad. Sci. USA 103: 18380.] Proc. Natl. Acad. Sci. USA 103: 13174–13179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Soltys J., Knight J., Scharf E., Pitt D., Mao-Draayer Y. 2014. IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients: implication of novel neurotensin/NTSR1 pathway in neuroprotection. Am. J. Transl. Res. 6: 312–319. [PMC free article] [PubMed] [Google Scholar]
- 15.Aarum J., Sandberg K., Haeberlein S. L., Persson M. A. 2003. Migration and differentiation of neural precursor cells can be directed by microglia. Proc. Natl. Acad. Sci. USA 100: 15983–15988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Nakanishi M., Niidome T., Matsuda S., Akaike A., Kihara T., Sugimoto H. 2007. Microglia-derived interleukin-6 and leukemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur. J. Neurosci. 25: 649–658. [DOI] [PubMed] [Google Scholar]
- 17.Monje M. L., Toda H., Palmer T. D. 2003. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760–1765. [DOI] [PubMed] [Google Scholar]
- 18.Chen Z., Palmer T. D. 2013. Differential roles of TNFR1 and TNFR2 signaling in adult hippocampal neurogenesis. Brain Behav. Immun. 30: 45–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Yoneyama M., Shiba T., Hasebe S., Ogita K. 2011. Adult neurogenesis is regulated by endogenous factors produced during neurodegeneration. J. Pharmacol. Sci. 115: 425–432. [DOI] [PubMed] [Google Scholar]
- 20.Moriyama M., Fukuhara T., Britschgi M., He Y., Narasimhan R., Villeda S., Molina H., Huber B. T., Holers M., Wyss-Coray T. 2011. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J. Neurosci. 31: 3981–3989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Shinjyo N., de Pablo Y., Pekny M., Pekna M. 2016. Complement peptide C3a promotes astrocyte survival in response to ischemic stress. Mol. Neurobiol. 53: 3076–3087. [DOI] [PubMed] [Google Scholar]
- 22.Anderson A. J., Haus D. L., Hooshmand M. J., Perez H., Sontag C. J., Cummings B. J. 2011. Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient? Regen. Med. 6: 367–406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Luchetti S., Beck K. D., Galvan M. D., Silva R., Cummings B. J., Anderson A. 2010. Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ and NOD-scid mice after contusion spinal cord injury. J. Neurotrauma 27: 411–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Nguyen H. X., O’Barr T. J., Anderson A. J. 2007. Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. J. Neurochem. 102: 900–912. [DOI] [PubMed] [Google Scholar]
- 25.Crowley L. C., Scott A. P., Marfell B. J., Boughaba J. A., Chojnowski G., Waterhouse N. J. 2016. Measuring cell death by propidium iodide uptake and flow cytometry. Cold Spring Harb. Protoc. 2016: pdb prot087163. [DOI] [PubMed] [Google Scholar]
- 26.Uchida N., Buck D. W., He D., Reitsma M. J., Masek M., Phan T. V., Tsukamoto A. S., Gage F. H., Weissman I. L. 2000. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA 97: 14720–14725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Tamaki S., Eckert K., He D., Sutton R., Doshe M., Jain G., Tushinski R., Reitsma M., Harris B., Tsukamoto A., et al. 2002. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J. Neurosci. Res. 69: 976–986. [DOI] [PubMed] [Google Scholar]
- 28.Piltti K. M., Haus D. L., Do E., Perez H., Anderson A. J., Cummings B. J. 2011. Computer-aided 2D and 3D quantification of human stem cell fate from in vitro samples using Volocity high performance image analysis software. Stem Cell Res. (Amst.) 7: 256–263. [DOI] [PubMed] [Google Scholar]
- 29.Burger R., Bader A., Kirschfink M., Rother U., Schrod L., Wörner I., Zilow G. 1987. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clin. Exp. Immunol. 68: 703–711. [PMC free article] [PubMed] [Google Scholar]
- 30.Selmaj K. W., Farooq M., Norton W. T., Raine C. S., Brosnan C. F. 1990. Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumor necrosis factor. J. Immunol. 144: 129–135. [PubMed] [Google Scholar]
- 31.Zgraggen S., Huggenberger R., Kerl K., Detmar M. 2014. An important role of the SDF-1/CXCR4 axis in chronic skin inflammation. PLoS One 9: e93665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Vaithilingam A., Teixeira J. E., Miller P. J., Heron B. T., Huston C. D. 2012. Entamoeba histolytica cell surface calreticulin binds human c1q and functions in amebic phagocytosis of host cells. Infect. Immun. 80: 2008–2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hooshmand M. J., Sontag C. J., Uchida N., Tamaki S., Anderson A. J., Cummings B. J. 2009. Analysis of host-mediated repair mechanisms after human CNS-stem cell transplantation for spinal cord injury: correlation of engraftment with recovery. PLoS One 4: e5871. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Cummings B. J., Uchida N., Tamaki S. J., Salazar D. L., Hooshmand M., Summers R., Gage F. H., Anderson A. J. 2005. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc. Natl. Acad. Sci. USA 102: 14069–14074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Anderson A. J., Su J. H., Cotman C. W. 1996. DNA damage and apoptosis in Alzheimer’s disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16: 1710–1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sontag C. J., Uchida N., Cummings B. J., Anderson A. J. 2014. Injury to the spinal cord niche alters the engraftment dynamics of human neural stem cells. Stem Cell Rep. 2: 620–632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Joelving F. C., Billeskov R., Christensen J. R., West M., Pakkenberg B. 2006. Hippocampal neuron and glial cell numbers in Parkinson’s disease: a stereological study. Hippocampus 16: 826–833. [DOI] [PubMed] [Google Scholar]
- 38.Politis P. K., Thomaidou D., Matsas R. 2008. Coordination of cell cycle exit and differentiation of neuronal progenitors. Cell Cycle 7: 691–697. [DOI] [PubMed] [Google Scholar]
- 39.Ben-Hur T., Ben-Menachem O., Furer V., Einstein O., Mizrachi-Kol R., Grigoriadis N. 2003. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol. Cell. Neurosci. 24: 623–631. [DOI] [PubMed] [Google Scholar]
- 40.Zhang C., Jang S., Amadi O. C., Shimizu K., Lee R. T., Mitchell R. N. 2013. A sensitive chemotaxis assay using a novel microfluidic device. BioMed Res. Int. 2013: 373569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Imitola J., Raddassi K., Park K. I., Mueller F. J., Nieto M., Teng Y. D., Frenkel D., Li J., Sidman R. L., Walsh C. A., et al. 2004. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci. USA 101: 18117–18122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Lewellis S. W., Knaut H. 2012. Attractive guidance: how the chemokine SDF1/CXCL12 guides different cells to different locations. Semin. Cell Dev. Biol. 23: 333–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Bleul C. C., Fuhlbrigge R. C., Casasnovas J. M., Aiuti A., Springer T. A. 1996. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 184: 1101–1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Kokovay E., Goderie S., Wang Y., Lotz S., Lin G., Sun Y., Roysam B., Shen Q., Temple S. 2010. Adult SVZ lineage cells home to and leave the vascular niche via differential responses to SDF1/CXCR4 signaling. Cell Stem Cell 7: 163–173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Lacy P., Stow J. L. 2011. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 118: 9–18. [DOI] [PubMed] [Google Scholar]
- 46.Rot A., von Andrian U. H. 2004. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22: 891–928. [DOI] [PubMed] [Google Scholar]
- 47.Nguyen H. X., Galvan M. D., Anderson A. J. 2008. Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury. J. Neuroinflammation 5: 26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Taylor-Robinson D., Schorlemmer H. U., Furr P. M., Allison A. C. 1978. Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms. Clin. Exp. Immunol. 33: 486–494. [PMC free article] [PubMed] [Google Scholar]
- 49.Zhou A. Q., Herriott M. J., Leu R. W. 1991. Kinetics of the biosynthesis of complement subcomponent C1q by murine macrophages: LPS, immune complexes, and zymosan alone and in combination with interferon-gamma. J. Leukoc. Biol. 50: 453–463. [DOI] [PubMed] [Google Scholar]
- 50.Camous L., Roumenina L., Bigot S., Brachemi S., Frémeaux-Bacchi V., Lesavre P., Halbwachs-Mecarelli L. 2011. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117: 1340–1349. [DOI] [PubMed] [Google Scholar]
- 51.Okuda T. 1991. Murine polymorphonuclear leukocytes synthesize and secrete the third component and factor B of complement. Int. Immunol. 3: 293–296. [DOI] [PubMed] [Google Scholar]
- 52.Rahpeymai Y., Hietala M. A., Wilhelmsson U., Fotheringham A., Davies I., Nilsson A. K., Zwirner J., Wetsel R. A., Gerard C., Pekny M., Pekna M. 2006. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 25: 1364–1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Botto M., Lissandrini D., Sorio C., Walport M. J. 1992. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J. Immunol. 149: 1348–1355. [PubMed] [Google Scholar]
- 54.Bentley C., Fries W., Brade V. 1978. Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro. Immunology 35: 971–980. [PMC free article] [PubMed] [Google Scholar]
- 55.Bexborn F., Andersson P. O., Chen H., Nilsson B., Ekdahl K. N. 2008. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol. Immunol. 45: 2370–2379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wirthmueller U., Dewald B., Thelen M., Schäfer M. K., Stover C., Whaley K., North J., Eggleton P., Reid K. B., Schwaeble W. J. 1997. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J. Immunol. 158: 4444–4451. [PubMed] [Google Scholar]
- 57.Zewde N., Gorham R. D., Jr., Dorado A., Morikis D. 2016. Quantitative modeling of the alternative pathway of the complement system. PLoS One 11: e0152337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Schwartz L. B., Kawahara M. S., Hugli T. E., Vik D., Fearon D. T., Austen K. F. 1983. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J. Immunol. 130: 1891–1895. [PubMed] [Google Scholar]
- 59.Yuan X., Shan M., You R., Frazier M. V., Hong M. J., Wetsel R. A., Drouin S., Seryshev A., Song L. Z., Cornwell L., et al. 2015. Activation of C3a receptor is required in cigarette smoke-mediated emphysema. Mucosal Immunol. 8: 874–885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Johnson U., Ohlsson K., Olsson I. 1976. Effects of granulocyte neutral proteases on complement components. Scand. J. Immunol. 5: 421–426. [DOI] [PubMed] [Google Scholar]
- 61.Venge P., Olsson I. 1975. Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. J. Immunol. 115: 1505–1508. [PubMed] [Google Scholar]
- 62.Des Prez R. M., Bryan C. S., Hawiger J., Colley D. G. 1975. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid. Infect. Immun. 11: 1235–1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Tharp W. G., Yadav R., Irimia D., Upadhyaya A., Samadani A., Hurtado O., Liu S. Y., Munisamy S., Brainard D. M., Mahon M. J., et al. 2006. Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo. J. Leukoc. Biol. 79: 539–554. [DOI] [PubMed] [Google Scholar]
- 64.Vianello F., Papeta N., Chen T., Kraft P., White N., Hart W. K., Kircher M. F., Swart E., Rhee S., Palù G., et al. 2006. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J. Immunol. 176: 2902–2914. [DOI] [PubMed] [Google Scholar]
- 65.Ricci-Vitiani L., Casalbore P., Petrucci G., Lauretti L., Montano N., Larocca L. M., Falchetti M. L., Lombardi D. G., Gerevini V. D., Cenciarelli C., et al. 2006. Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. Neurol. Res. 28: 488–492. [DOI] [PubMed] [Google Scholar]
- 66.Johansson S., Price J., Modo M. 2008. Effect of inflammatory cytokines on major histocompatibility complex expression and differentiation of human neural stem/progenitor cells. Stem Cells 26: 2444–2454. [DOI] [PubMed] [Google Scholar]
- 67.Salazar D. L., Uchida N., Hamers F. P., Cummings B. J., Anderson A. J. 2010. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One 5: e12272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Nguyen H., Saiwai M. H. H., Maddox J., Salehi A., Salazar D., Uchida N., Anderson A. Systemic neutrophil depletion modulates the migration and fate of transplanted human neural stem cells to rescue functional repair. J. Neurosci. In press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Benoit M. E., Tenner A. J. 2011. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J. Neurosci. 31: 3459–3469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Reboul A., Prandini M. H., Bensa J. C., Colomb M. G. 1985. Characterization of C1q, C1s and C-1 Inh synthesized by stimulated human monocytes in vitro. FEBS Lett. 190: 65–68. [DOI] [PubMed] [Google Scholar]
- 71.Bensa J. C., Reboul A., Colomb M. G. 1983. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem. J. 216: 385–392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Arnett H. A., Wang Y., Matsushima G. K., Suzuki K., Ting J. P. 2003. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J. Neurosci. 23: 9824–9832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Anderson A. J., Robert S., Huang W., Young W., Cotman C. W. 2004. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21: 1831–1846. [DOI] [PubMed] [Google Scholar]
- 74.Stephan A. H., Madison D. V., Mateos J. M., Fraser D. A., Lovelett E. A., Coutellier L., Kim L., Tsai H. H., Huang E. J., Rowitch D. H., et al. 2013. A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci. 33: 13460–13474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Stevens B., Allen N. J., Vazquez L. E., Howell G. R., Christopherson K. S., Nouri N., Micheva K. D., Mehalow A. K., Huberman A. D., Stafford B., et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164–1178. [DOI] [PubMed] [Google Scholar]
- 76.Tahtouh M., Croq F., Vizioli J., Sautiere P. E., Van Camp C., Salzet M., Daha M. R., Pestel J., Lefebvre C. 2009. Evidence for a novel chemotactic C1q domain-containing factor in the leech nerve cord. Mol. Immunol. 46: 523–531. [DOI] [PubMed] [Google Scholar]
- 77.Bogestål Y. R., Barnum S. R., Smith P. L., Mattisson V., Pekny M., Pekna M. 2007. Signaling through C5aR is not involved in basal neurogenesis. J. Neurosci. Res. 85: 2892–2897. [DOI] [PubMed] [Google Scholar]
- 78.Shinjyo N., Ståhlberg A., Dragunow M., Pekny M., Pekna M. 2009. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 27: 2824–2832. [DOI] [PubMed] [Google Scholar]
- 79.Johswich K., Klos A. 2007. C5L2: an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)? Adv. Exp. Med. Biol. 598: 159–180. [DOI] [PubMed] [Google Scholar]
- 80.Chen E., Xu D., Lan X., Jia B., Sun L., Zheng J. C., Peng H. 2013. A novel role of the STAT3 pathway in brain inflammation-induced human neural progenitor cell differentiation. Curr. Mol. Med. 13: 1474–1484. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Sofroniew M. V. 2015. Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16: 249–263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Carpentier P. A., Palmer T. D. 2009. Immune influence on adult neural stem cell regulation and function. Neuron 64: 79–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U. K., Pitsillides C. M., Spencer J. A., Kimlinger T., Ghobrial J. M., Jia X., et al. 2007. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 2708–2717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Vianello F., Olszak I. T., Poznansky M. C. 2005. Fugetaxis: active movement of leukocytes away from a chemokinetic agent. J. Mol. Med. (Berl.) 83: 752–763. [DOI] [PubMed] [Google Scholar]
- 85.Tenner A. J., Volkin D. B. 1986. Complement subcomponent C1q secreted by cultured human monocytes has subunit structure identical with that of serum C1q. Biochem. J. 233: 451–458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Ferluga J., Schorlemmer H. U., Baptista L. C., Allison A. C. 1978. Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects. Clin. Exp. Immunol. 31: 512–517. [PMC free article] [PubMed] [Google Scholar]
- 87.Kigerl K. A., Gensel J. C., Ankeny D. P., Alexander J. K., Donnelly D. J., Popovich P. G. 2009. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29: 13435–13444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677–686. [DOI] [PubMed] [Google Scholar]
- 89.Heppner F. L., Ransohoff R. M., Becher B. 2015. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16: 358–372. [DOI] [PubMed] [Google Scholar]
- 90.Roybon L., Lamas N. J., Garcia-Diaz A., Yang E. J., Sattler R., Jackson-Lewis V., Kim Y. A., Kachel C. A., Rothstein J. D., Przedborski S., et al. 2013. Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Reports 4: 1035–1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Shaltouki A., Peng J., Liu Q., Rao M. S., Zeng X. 2013. Efficient generation of astrocytes from human pluripotent stem cells in defined conditions. Stem Cells 31: 941–952. [DOI] [PubMed] [Google Scholar]
- 92.Haas C., Fischer I. 2013. Human astrocytes derived from glial restricted progenitors support regeneration of the injured spinal cord. J. Neurotrauma 30: 1035–1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Corti S., Nizzardo M., Simone C., Falcone M., Donadoni C., Salani S., Rizzo F., Nardini M., Riboldi G., Magri F., et al. 2012. Direct reprogramming of human astrocytes into neural stem cells and neurons. Exp. Cell Res. 318: 1528–1541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Schneider L., Pellegatta S., Favaro R., Pisati F., Roncaglia P., Testa G., Nicolis S. K., Finocchiaro G., d’Adda di Fagagna F. 2013. DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT. Stem Cell Rep. 1: 123–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Obayashi S., Tabunoki H., Kim S. U., Satoh J. 2009. Gene expression profiling of human neural progenitor cells following the serum-induced astrocyte differentiation. Cell. Mol. Neurobiol. 29: 423–438. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.